Curetis
to Publish its 2017 Annual Results on April 30,
2018
-
Company to host earnings conference call and webcast
Amsterdam, the Netherlands, San
Diego, CA, USA and Holzgerlingen, Germany, April 23, 2017,
01:00 am EDT -- Curetis N.V. (the "Company"
and, together with Curetis GmbH, "Curetis"), a
developer of next-level molecular diagnostic solutions, today
announced that it will publish its full-year 2017 financial results
on April 30, 2018. In addition, the Company will host a public
earnings conference call and webcast on April 30, 2018, at 03:00 pm
CET / 09:00am EDT to present the financial results of 2017,
highlight the most important events and provide an outlook for
2018.
A slide presentation accompanying the investor
update conference call will be accessible at
https://webcasts.eqs.com/curetis20180430/no-audio.
To access the call, please dial the following
numbers using the passcode 93120684#
BEL: +32 11500307
D: +49 69 222229043
NL: +31 1071 372 73
UK: +44 20 30092452
US: +1 855 4027766
For further international dial-in numbers, please
open the following link:
http://events.arkadin.com/ev/docs/International%20Access%20Numbers_%20UKFELBRI1_SU7.pdf
The conference call will be supplemented by a
presentation and a webcast, which can be accessed after the call at
http://www.curetis.com/en/investors/financial-reports-and-conferences/financial-reports.html
###
About the Unyvero System
The Unyvero System with the
Unyvero LRT Cartridge is the first, most comprehensive molecular
diagnostics (MDx) product for lower respiratory tract infections
that has been granted clearance by the FDA. With 29 multiplexed PCR
assays it can detect more than 30 Gram-positive and Gram-negative
bacterial organisms known to cause lower respiratory tract
infections, as well as 10 genetic markers for antibiotic
resistance, including carbapenem and 3rd generation cephalosporins.
Preparations for a future submission of bronchoalveolar lavage
(BAL) sample types for use with the LRT Cartridge are progressing,
and the Company intends to request a pre-submission meeting in due
course. The Company also is already collecting patient samples for
a multi-center FDA study for its Unyvero IJI Cartridge for the
detection of invasive joint infections. Further Unyvero Cartridges
with unique panels designed for the rapid diagnosis of microbial
and viral infections are in preparation.
About Curetis
Curetis N.V. (Euronext: CURE) is a
leading provider of innovative solutions for molecular microbiology
designed to address the global challenge of diagnosing severe
infectious diseases and identifying antibiotic resistances in
hospitalized patients.
Curetis' Unyvero System is a
versatile, fast and highly automated molecular diagnostic platform
for easy-to-use, cartridge-based solutions for the comprehensive
and rapid detection of pathogens and antimicrobial resistance
markers in a range of severe infectious disease indications.
Results are available within hours, a process that can take days or
even weeks if performed with standard diagnostic procedures, and
thereby facilitates improved patient outcomes, stringent antibiotic
stewardship and health economic benefits. Unyvero
in-vitro-diagnostic (IVD) products are marketed in Europe, the
Middle East, Asia, and in the U.S.
Curetis' wholly-owned subsidiary
Ares Genetics GmbH offers next-generation solutions for infectious
disease diagnostics and therapeutics. ARES' technology platform
combines the world's most comprehensive database on the genetics of
antimicrobial resistances with advanced bioinformatics and
artificial intelligence.
For further information, please
visit www.curetis.com and
www.ares-genetics.com.
Legal Disclaimer
This announcement contains inside
information. This is a public announcement pursuant to article 17
paragraph 1 of the European Market Abuse Regulation (596/2014).
This document constitutes neither
an offer to buy nor to subscribe for securities and neither this
document nor any part of it should form the basis of any investment
decision in Curetis.
The information contained in this
press release has been carefully prepared. However, Curetis bears
and assumes no liability of whatever kind for the correctness and
completeness of the information provided herein. Curetis does not
assume an obligation of whatever kind to update or correct
information contained in this press release whether as a result of
new information, future events or for other reasons.
This press release includes
statements that are, or may be deemed to be, "forward-looking
statements". These forward-looking statements can be identified by
the use of forward-looking terminology, including the terms
"believes", "estimates", "anticipates", "expects", "intends",
"may", "will", or "should", and include statements Curetis makes
concerning the intended results of its strategy. By their nature,
forward-looking statements involve risks and uncertainties and
readers are cautioned that any such forward-looking statements are
not guarantees of future performance. Curetis' actual results may
differ materially from those predicted by the forward-looking
statements. Curetis undertakes no obligation to publicly update or
revise forward-looking statements, except as may be required by
law.
Contact Details
Curetis GmbH
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com
International Media &
Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info@akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor
Inquiries
The Ruth Group
Lee Roth
lroth@theruthgroup.com
Tel. +1 646 536 7012